Malignant hyperthermia.
D000758:Anesthesia / Q000009:adverse effects*; D001285:Atropine / Q000009:adverse effects; D001639:Bicarbonates / Q000627:therapeutic use; D003402:Creatine Kinase / Q000097:blood; D003521:Cyclopropanes / Q000009:adverse effects; D005260:Female; D006221:Halothane / Q000009:adverse effects; D006801:Humans; D006919:Hydroxyzine / Q000009:adverse effects; D008297:Male; D008305:Malignant Hyperthermia / Q000139:chemically induced* / Q000188:drug therapy / Q000201:enzymology / Q000209:etiology / Q000235:genetics / Q000628:therapy; D008614:Meperidine / Q000009:adverse effects; D009467:Neuromuscular Depolarizing Agents; D009609:Nitrous Oxide / Q000009:adverse effects; D013874:Thiopental / Q000009:adverse effects
D001639:Bicarbonates; D003521:Cyclopropanes; D009467:Neuromuscular Depolarizing Agents; D006919:Hydroxyzine; D001285:Atropine; D008614:Meperidine; D003402:Creatine Kinase; D013874:Thiopental; D009609:Nitrous Oxide; D006221:Halothane